Lani Ibarra

Ms. Ibarra has over 25 years of pharmaceutical industry experience in clinical operations, project management, medical writing, and clinical finance. Prior to joining ShouTi, Ms. Ibarra was Vice President of Global Clinical Operations at Molecular Partners AG, where she was responsible for driving the execution of oncology programs in the U.S. and Europe. For more than six years, Ms. Ibarra was Vice President of Clinical Operations and Medical Writing at Dynavax Technologies, where she built and led the clinical development operations teams responsible for the BLA submission and approval of Heplisav-B®. Ms. Ibarra has held multiple roles of increasing responsibility in clinical development operations in oncology, infectious disease, ophthalmology, and Alzheimer’s disease for biotech companies including Kartos Therapeutics, CoMentis, InterMune, FibroGen, Gilead Sciences, and Novartis. Ms. Ibarra started her career in the industry as a formulations chemist. She earned an M.S. in biological science from Stanford University and a B.A. in biology from the University of California, Berkeley.